Matrix-M1

BIOLOGICAL2 trials

Sponsors

University of Oxford, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

EBVEpstein-Barr Virus InfectionInfectious MononucleosisMalaria

Phase 1

A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1

CompletedNCT02572388

University of OxfordMalaria

Start: 2015-10-15End: 2017-08-29Updated: 2019-11-12

Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection

Active, not recruitingNCT04645147

National Institute of Allergy and Infectious Diseases (NIAID)EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis

Start: 2022-03-29End: 2026-07-01Updated: 2025-07-17

Related Papers

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

2025-01-104 citations